What is Caldera Therapeutics?
Caldera Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating first-in-class bispecific antibodies. Its primary focus is on CLD-423, a dual-acting therapeutic targeting the IL-23p19 and TL1A pathways. This innovative approach is designed to treat severe inflammatory bowel disease (IBD) and a range of other immunologic and inflammatory conditions. The company's strategy leverages deep expertise in IBD therapeutics and a proven track record in building successful biotechnology ventures.
How much funding has Caldera Therapeutics raised?
Caldera Therapeutics has raised a total of $112.5M across 2 funding rounds:
Series A
$75M
Other Financing Round
$37.5M
Series A (2026): $75M with participation from Atlas Venture and venBio Partners
Other Financing Round (2026): $37.5M led by Janus Henderson Investors, Omega Alpha Spac, and Wellington Management
Key Investors in Caldera Therapeutics
Atlas Venture
Atlas Venture is a venture capital firm specializing in early-stage biotechnology, focusing on creating and building companies that translate cutting-edge science into life-changing medicines. They partner with entrepreneurs to support innovative biotech startups.
venBio Partners
venBio Partners is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, with a focus on novel therapeutics for unmet medical needs. They emphasize positioning portfolio companies for potential acquisition.
Wellington Management
Wellington Management is a global, independent investment management firm providing portfolio management, research, and tailored investment solutions across various asset classes to institutional clients.
What's next for Caldera Therapeutics?
The substantial enterprise-level funding and recent strategic investment position Caldera Therapeutics for significant growth and pipeline acceleration. This capital infusion is anticipated to fuel the progression of CLD-423 through critical clinical trials and support the expansion of its research and development capabilities. The company's focus on validated biological targets, combined with experienced leadership, suggests a strategic path toward addressing unmet needs in autoimmune and inflammatory diseases, potentially leading to future partnerships or market entry.
See full Caldera Therapeutics company page
